Efeito da suplementação de dois compostos de zinco nos parâmetros comportamentais, bioquímicos e histológicos em modelo animal de diabetes Mellitus tipo 1

• Ano de defesa: 2018
• Autor(a) principal: Cavalcanti, Christiane Leite
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal da Paraíba; Brasil; Ciências da Nutrição; Programa de Pós-Graduação em Ciências da Nutrição; UFPB
• Palavras-chave em Português: Ansiedade; Depressão; Estresse oxidativo; Glicemia; Histologia; Suplementação nutricional; Anxiety; Depression; Oxidative stress; Glycemia; Histology; Nutritional supplementation; CNPQ::CIENCIAS DA SAUDE::NUTRICAO
• Link de acesso: https://repositorio.ufpb.br/jspui/handle/123456789/13444

The Zinc (Zn) plays a role in improving insulin sensitivity, so its supplementation has been used as adjuvant treatment of Diabetes Mellitus, however, there is no consensus as to the efficacy of the compounds used. In this sense, the accomplishment of this study aimed to evaluate the effect of the supplementation of two Zn compounds on the behavioral, biochemical and histological parameters in an experimental model of Type 1 Diabetes Mellitus. Fifty four male adult rats were randomized into six groups: Control (C = n = 8); Supplementary with Zn Sulphate (SZ; n = 8); Supplementary with Zn Gluconate (GZ; n = 8); Diabetic (D; n = 10); Diabetic Zn Sulfate Supplementary (DSZ; n = 10) and Diabetic Zn Gluconate Supplementary (DGZ; n = 10). The SZ and DSZ groups received oral supplementation of Zn Sulfate and the GZ and DGZ groups received oral Zn Gluconate supplementation at both the dose (15 mg/kg body weight) for 4 weeks. The Data (mean±SEM) were analyzed by the Mann-Whitney test or ANOVA, followed by Tukey posthoc, with significance level of p<0.05. The partial results were: there were no significant differences regarding the classic symptoms of the disease, but group D presented significant loss of body mass and reduction of the murinometric measures (p<0.05) compared to the DSZ and DGZ groups, indicating that Zn supplementation attenuated the loss of weight in diabetes. Regarding the behavioral parameters, the DSZ group presented a longer residence time and a greater number of entries in the open arms in the Elevated Cross Labyrinth Test (p<0.05); greater ambulation and shorter time of immobility in the Open Field Test (p<0.05) and less time of immobility in the Forced Swimming Test (p<0.05); while the DGZ group presented lower immobility time and longer swimming time in the Forced Swim Test (p<0.05), with no statistical differences in the other tests, indicating that supplementation with Zn Sulphate presented an anxiolytic effect and Gluconate supplementation of Zn presented antidepressant effect in diabetic animals, corroborating with the results of the histological analysis, with attenuation of the cerebral histological alterations as reduction of ischemic neurons and hemorrhage of the animals of the DGZ group. The DSZ group presented better glycemic control compared to the D and DGZ groups, considering HbA1c and glycemia values in the Oral Glucose Tolerance Test and the Insulin Tolerance Test (p<0.05), suggesting a better uptake of the resulting glucose of Zn Sulfate supplementation. However, the DSZ and DGZ groups presented negative changes in the lipid profile (p<0.05). Total Antioxidant Capacity levels were increased in the DSZ and DGZ groups, compared to the D group (p<0.05), however there was no significant difference in Malondialdehyde levels. The DSZ group presented improvement in liver function, with attenuation of histological changes, compared to D and DGZ groups (p<0.05). The DSZ and DGZ groups showed improvement in renal function, compared to group D (p<0.05); however, the DGZ group presented a greater protective effect of the renal tissues compared to the DSZ group. The results indicate a greater therapeutic effect of Zn Sulphate compared to Zn Gluconate, improving glycemic control, increasing antioxidant activity and attenuating liver and kidney tissue damage. However, supplementation with the two Zn compounds resulted in adverse reactions on the lipid profile, which may contribute to the development of cardiovascular complications, therefore, supplementation should be monitored within the tolerable limit.